Abstract CT188: A Phase I trial of AVA6000, a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors

Banerji, U., Cook, N., Anthoney, A. et al. (11 more authors) (2024) Abstract CT188: A Phase I trial of AVA6000, a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors. In: Cancer Research. AACR Annual Meeting 2024, 05-10 Apr 2024, San Diego, USA. American Association for Cancer Research, ct188-ct188. ISSN: 0008-5472. EISSN: 1538-7445.

Metadata

Item Type: Proceedings Paper
Authors/Creators:
  • Banerji, U.
  • Cook, N.
  • Anthoney, A.
  • Plummer, R.
  • Tap, W.D.
  • Evans, J.T.
  • Cranmer, L.D.
  • Plummer, C.
  • Loadman, P.
  • Lahu, G.
  • Jones, H.S.
  • Kinnersley, N.
  • McLaughlin, F.
  • Twelves, C.
Dates:
  • Published: 1 April 2024
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds)
Date Deposited: 27 Oct 2025 16:17
Last Modified: 27 Oct 2025 16:17
Status: Published
Publisher: American Association for Cancer Research
Identification Number: 10.1158/1538-7445.am2024-ct188
Open Archives Initiative ID (OAI ID):

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Export

Statistics


CORE (COnnecting REpositories)